Eisai Anticipates Significant Growth with China Alzheimer's Launch

Eisai plans to launch its Alzheimer's drug Leqembi to 1,500 patients in China this year, with expectations of significant growth in 2025 as more convenient blood tests become available. Eli Lilly is also developing a similar treatment and has filed for approval in China. The introduction of blood tests is expected to increase interest in the treatment. However, China's healthcare system is currently ill-prepared to provide timely access to Alzheimer's treatments, with limited diagnosis and treatment rates and a lack of specialty care in rural areas.